GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman SyndromeGlobeNewsWire • 06/10/21
Ultragenyx (RARE) Down 7.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/03/21
GeneTx and Ultragenyx Receive Clearance from Health Canada to Begin Clinical Study of GTX-102 in Canada for the Treatment of Angelman SyndromeGlobeNewsWire • 05/19/21
Ultragenyx's Gene Therapies For Genetic Metabolic Disorders Show Longer-Term Durable ResponsesBenzinga • 05/14/21
Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual MeetingGlobeNewsWire • 05/14/21
Kyowa Kirin Receives Positive CHMP Opinion for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH), a Rare Metabolic Bone DisorderBusiness Wire • 05/10/21
Allstate, Booking, CyberArk, Hilton and More Thursday Afternoon Analyst Calls24/7 Wall Street • 05/06/21
Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
Ultragenyx to Host Conference Call for First Quarter 2021 Financial Results and Corporate UpdateGlobeNewsWire • 04/28/21
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual MeetingGlobeNewsWire • 04/27/21
n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare DiseasesBusiness Wire • 04/05/21